Induced Pluripotent Stem Cell (iPSC) Market Study Highlights How Industry Demand Is Evolving

The induced pluripotent stem cell (iPSC) sector is poised for remarkable advancement as its applications continue to expand across healthcare and research fields. Driven by increasing investments and scientific breakthroughs, this market is set to redefine regenerative medicine and personalized therapies over the coming years. Below is an overview of the market's growth prospects, leading players, driving forces, current trends, and segmentation details shaping the future of iPSC technology.

Projection of Market Growth for Induced Pluripotent Stem Cells Through 2030
The iPSC market is projected to experience robust growth, reaching a valuation of $5.75 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.3%. The anticipated increase is largely attributed to the broadening scope of regenerative medicine, rising demand for tailored therapies, growing investments in cell and gene therapies, and greater adoption of iPSCs in research areas such as neurology and cardiology. Additionally, supportive regulatory frameworks for advanced therapies provide a favorable environment for continued innovation. Key trends expected to influence the market include enhanced use of iPSCs in disease modeling, drug discovery, toxicity testing, and the development of patient-specific cell lines. Progress in improving reprogramming methods and cell stability also plays a significant role in propelling the market forward.

The induced pluripotent stem cell (ipsc) market size has grown strongly in recent years. It will grow from $3.67 billion in 2025 to $4.02 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to breakthroughs in cellular reprogramming research, ethical concerns around embryonic stem cells, increased funding for stem cell research, growth of academic research collaborations, rising prevalence of chronic and degenerative diseases.

Download a free sample of the induced pluripotent stem cell (ipsc) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Main Players Driving the Induced Pluripotent Stem Cell Market Today
A diverse group of companies leads the iPSC market, including industry giants and specialized biotechnology firms. Notable participants are FUJIFILM Holdings Corporation (through FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, and Japan Tissue Engineering Co., Ltd. Other important contributors comprise Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW Therapeutics, Fosun Kite Biotechnology, and Shanghai UniCar Therapy. The list further extends to SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, Parexel, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, and BioHeart.

Significant Partnership Enhancing iPSC Product Offerings
In May 2024, Theragent Inc., a biotechnology company based in the United States, forged a partnership with Pluristyx Inc., another US-based biotech firm specializing in iPSC products. Through this collaboration, Theragent aims to broaden its product portfolio by integrating Pluristyx's expertise and offerings related to induced pluripotent stem cells. This strategic alliance is expected to accelerate innovation and market reach in the iPSC domain.

View the full induced pluripotent stem cell (ipsc) market report:
https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Collaborations and Technological Advances Fueling iPSC Market Growth
Key industry players are actively joining forces to push the boundaries of iPSC technology, focusing on enhancing regenerative medicine, refining disease models, speeding up drug discovery, and creating personalized therapy solutions. Induced pluripotent stem cell technology involves reprogramming adult somatic cells, such as skin or blood cells, back into a pluripotent state that allows differentiation into various cell types. An example of such progress occurred in April 2024 when Singapore-based SCG Cell Therapy Pte Ltd partnered with the Agency for Science, Technology and Research, a local statutory board. Together, they launched joint laboratories aimed at advancing cellular immunotherapies, supported by nearly S$30 million in funding. Their goal is to develop scalable manufacturing processes for Good Manufacturing Practice (GMP)-grade iPSC products that can facilitate the transition from lab research to clinical therapies.

Defining the Induced Pluripotent Stem Cell Market Segments
The iPSC market is organized into several key segments for a comprehensive analysis:
1) By Derived Cell Type: This includes hepatocytes, fibroblasts, keratinocytes, amniotic cells, and other cell types derived from iPSCs.
2) By Application: The main uses cover academic research, drug discovery and toxicity testing, regenerative medicine, and cell and gene therapy.
3) By End-User: The market is segmented into hospitals and research laboratories as primary consumers.

Further breakdowns provide more focused insights:
- Hepatocytes include iPSC-derived liver cells used for drug toxicity tests, disease modeling, and regenerative treatments.
- Fibroblasts cover skin cells derived from iPSCs applied in wound healing, tissue repair, and fibroblast-related disease studies.
- Keratinocytes refer to iPSC-derived skin cells utilized in dermatological research and skin regeneration therapies.
- Amniotic cells pertain to prenatal research and regenerative applications involving amniotic fluid-derived cells from iPSCs.
- Other derived cell types incorporate neurons for neurological disease modeling, cardiomyocytes for heart disease investigations, and endothelial cells for vascular research.

This detailed segmentation helps clarify the diverse applications and cell types integral to the ongoing development and commercialization of iPSC technologies.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.